Identification of a C3b-specific nanobody that does not bind C3 and blocks alternative pathway convertases
Authors:
- Eva M StruijfESEva M Struijf
- Bart W. BardoelBBBart W. Bardoel
- Joanne E. van KeulenJKJoanne E. van Keulen
- Maartje RuykenMRMaartje Ruyken
- Douwe J. DijkstraDDDouwe J. Dijkstra
- Gillian DekkersGDGillian Dekkers
- Piet GrosPGPiet Gros
- Raimond HeukersRHRaimond Heukers
- Dani A.C. HeesterbeekDHDani A.C. Heesterbeek
- Suzan H.M. RooijakkersSRSuzan H.M. Rooijakkers
- Jamie S. DepelteauJDJamie S. Depelteau
Preprint
Abstract
The human complement system is a protein network in blood and other body fluids that fights invading pathogens and is involved in maintaining homeostasis. A central step in the complement cascade is the conversion of complement protein C3 to C3b by convertase enzymes. Upon cleavage of C3, the nascent C3b molecule undergoes a large conformational change which exposes new epitopes. Molecules that discriminate between C3b and C3 could provide a powerful tool to selectively bind surface-bound complement activation products while leaving the circulating precursors untouched. In this study, we developed C3b-specific nanobodies by generating phage libraries from llamas immunized with purified and surface-bound C3b. We describe UNbC3b-1 as a high-affinity binder that recognizes soluble and surface-bound C3b molecules but does not bind to C3 in its native state. A 4.2 Å structure of the UNbC3b-1:C3b complex generated by cryogenic electron microscopy shows that UNbC3b-1 binds C3b at the interface of MG3, MG4, and MG6, overlapping with the complement receptor immunoglobulin (CRIg) binding site. Functionally, we show that UNbC3b-1 inhibits complement activity in the alternative pathway (AP), likely by preventing association between substrate C3 and the AP C3 convertase (C3bBb). Altogether, nanobody UNbC3b-1 is a valuable tool to specifically bind C3b molecules and to selectively inhibit the AP convertases of the complement system.Keywords
Funding Information
- Netherlands Organization for Scientific Research (NWA.ID.17.036)
This publication has 47 references indexed in Scilit:
- Inhibition of cleavage of human complement component C5 and the R885H C5 variant by two distinct high affinity anti-C5 nanobodiesJournal of Biological Chemistry, 2023
- IMGT® Immunoinformatics Tools for Standardized V-DOMAIN Analysis2022
- Recombinant Limosilactobacillus (Lactobacillus) delivering nanobodies against Clostridium perfringens NetB and alpha toxin confers potential protection from necrotic enteritisMicrobiologyopen, 2022
- UCSF ChimeraX: Structure visualization for researchers, educators, and developersProtein Science, 2020
- Compendium of current complement therapeuticsMolecular Immunology, 2019
- Complement deficiencies and dysregulation: Pathophysiological consequences, modern analysis, and clinical managementMolecular Immunology, 2019
- The tick-over theory revisited: Is C3 a contact-activated protein?Immunobiology, 2012
- Selective and efficient inhibition of the alternative pathway of complement by a mAb that recognizes C3b/iC3bMolecular Immunology, 2006
- By-passing immunizationJournal of Molecular Biology, 1991
- Microassay for colorimetric estimation of complement activity in guinea pig, human and mouse serumJournal of Immunological Methods, 1983